Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …

Trastuzumab (TZM) is commonly used for target therapy in breast cancer patients with high
HER2 although the cardiotoxicity restricts its clinical usage. DNA damage and ferroptosis …

Background Trastuzumab is used, alone or in conjunction with standard chemotherapy, to
treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab …

Simple Summary Many cancer therapeutics may have a robust effect on target molecules
but lack the means of effective localization into tumor cells, thus displaying reduced …

Trastuzumab-induced cardiotoxicity (TIC) is a common and serious disease with abnormal
cardiac function. Accumulating evidence has indicated certain non-coding RNAs (ncRNAs) …

A 41-year-old female with human epidermal growth factor receptor 2 (HER2)(+) metastatic
breast cancer was admitted due to exertional dyspnea and othopnea. She had received 3 …

In the clinical setting, the term “cardiotoxicity” has been mostly used to denote a specific form
of cardiomyopathy associated with a variety of chemotherapeutic agents. 1, 2 In this context …

Trastuzumab is the first-line therapy for human epidermal growth factor receptor 2 (HER2)-
positive breast cancer. However, trastuzumab is associated with cardiotoxicity. It manifests …

We have read the comments1 about our case2 and are pleased to have a chance to discuss
conflicting points. We had presented a female with human epidermal growth factor receptor …

In the clinical setting, the term “cardiotoxicity” has been mostly used to denote a specific form
of cardiomyopathy associated with a variety of chemotherapeutic agents. 1, 2 In this context …